The pharmaceutical company on Wednesday announced that its wholly owned subsidiary, Eugia Pharma Specialities has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Lenalidomide Capsules.
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone. The said drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Revlimid Capsules, of Bristol-Myers Squibb Company.
The drug maker said that the product is expected to be launched in October 2023 (volume specific launch).
This is the 155th ANDA (including 9 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
The company reported 18.8% decline in consolidated net profit to Rs 491.26 crore in Q3 FY23 as against Rs 604.73 crore reported in Q3 FY22. Revenue from operations rose 6.7% year on year to Rs 6,387.97 crore in the quarter ended 31 December 2022.
Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients.
Shares of Aurobindo Pharma were up 0.33% to Rs 468.05 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app